Key result
Aspirin cancer prevention awareness remains at only ~19% among surveyed adults amid common bleeding concerns.
Why the study?
Aspirin could be offered for colorectal cancer prevention, but the views of the UK general population needed to be explored to inform future guidance.
What are the public perceptions and acceptability of aspirin for cancer preventive therapy among the UK general population aged 50-70 years?
Cross-Sectional (n=400)
What are the public perceptions and acceptability of aspirin for cancer preventive therapy among the UK general population aged 50-70 years?
A minority of the UK general population aged 50-70 is aware of aspirin's potential for cancer prevention, with acceptability influenced by personal or family cancer history and concerns about side effects.
Low awareness of aspirin for cancer prevention may limit uptake; leaves open how education can address side-effect concerns.
OBJECTIVES: Aspirin could be offered for colorectal cancer prevention for the UK general population. To ensure the views of the general population are considered in future guidance, we explored public perceptions of aspirin for preventive therapy. DESIGN: We conducted an online survey to investigate aspirin use, and awareness of aspirin for cancer prevention among the UK general population. We conducted semistructured interviews with a subsample of survey respondents to explore participants' acceptability towards aspirin for cancer preventive therapy. We analysed the interview data using reflexive thematic analysis and mapped the themes onto the Theoretical Domains Framework, and the Necessity and Concerns Framework. SETTING: Online survey and remote interviews. PARTICIPANTS: We recruited 400 UK respondents aged 50-70 years through a market research company to the survey. We purposefully sampled, recruited and interviewed 20 survey respondents. RESULTS: In the survey, 19.0% (76/400) of respondents were aware that aspirin can be used to prevent cancer. Among those who had previously taken aspirin, 1.9% (4/216) had taken it for cancer prevention. The interviews generated three themes: (1) perceived necessity of aspirin; (2) concerns about side effects; and (3) preferred information sources. Participants with a personal or family history of cancer were more likely to perceive aspirin as necessary for cancer prevention. Concerns about taking aspirin at higher doses and its side effects, such as gastrointestinal bleeding, were common. Many described wanting guidance and advice on aspirin to be communicated from sources perceived as trustworthy, such as healthcare professionals. CONCLUSIONS: Among the general population, those with a personal or family history of cancer may be more receptive towards taking aspirin for preventive therapy. Future policies and campaigns recommending aspirin may be of particular interest to these groups. Multiple considerations about the benefits and risks of aspirin highlight the need to support informed decisions on the medication.
No takes yet. Share an insight, caveat, or question.
Lloyd et al. (2023) conducted a cross-sectional in Cancer prevention (n=400). Aspirin was evaluated on Awareness that aspirin can be used to prevent cancer. In a survey of 400 UK adults aged 50-70, only 19.0% were aware that aspirin can be used to prevent cancer, and concerns about side effects like gastrointestinal bleeding were common.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: